TYPTF (Tryptamine Therapeutics) Growth Rank : 0 (As of Apr. 08, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics Growth Rank?

Tryptamine Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Tryptamine Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

TYP:Australia

Address

C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.tryptherapeutics.com

Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

From GuruFocus

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

By PRNewswire PRNewswire • 01-31-2022

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

By PRNewswire PRNewswire • 12-22-2021